Eicosapentaenoic acid (EPA) has been shown to attenuate muscle atrophy in cancer, starvation and hyperthermia by downregulating the increased expression of the ubiquitin-proteasome proteolytic pathway leading to a reduction in protein degradation. In the current study EPA (0.5 g/kg) administered to septic mice completely attenuated the increased protein degradation in skeletal muscle by preventing the increase in both gene expression and protein concentration of the alpha- and beta-subunits of the 20S proteasome, as well as functional activity of the proteasome, as measured by the 'chymotrypsin-like' enzyme activity. These results suggest that muscle protein catabolism in sepsis is mediated by the same intracellular signalling pathways as found in other catabolic conditions.
|Number of pages||3|
|Journal||Biochemical and Biophysical Research Communications|
|Early online date||12 Aug 2008|
|Publication status||Published - 17 Oct 2008|
- muscle atrophy
- ubiquitin-proteasome proteolysis
Khal, J., & Tisdale, M. J. (2008). Downregulation of muscle protein degradation in sepsis by eicosapentaenoic acid (EPA). Biochemical and Biophysical Research Communications, 375(2), 238-240. https://doi.org/10.1016/j.bbrc.2008.08.004